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Mutations and Their Role in Cancer 
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Recent preclinical and clinical studies have proved the long-standing hypothesis that 
tumors elicit adaptive immune responses and that the antigens driving effective T-cell 
response are neoantigens, i.e., peptides that are generated from somatically mutated 
genes. Hence, the characterization of neoantigens and the identification of the immu-
nogenic ones are of utmost importance for improving cancer immunotherapy and 
broadening its efficacy to a larger fraction of patients. In this review, we first introduce 
the methods used for the quantification of neoantigens using next-generation sequenc-
ing data and then summarize results obtained using these tools to characterize the 
neoantigen landscape in solid cancers. We then discuss the importance of neoantigens 
for cancer immunotherapy using checkpoint blockers, vaccination, and adoptive T-cell 
transfer. Finally, we give an overview over emerging aspects in cancer immunity, including 
tumor heterogeneity and immunoediting, and give an outlook on future prospects.
Keywords: next-generation sequencing, immunoediting, tumor heterogeneity, somatic mutations, cancer 
vaccines
iNTRODUCTiON
In the past decade, driven by technological advances major progress in cancer research and cancer 
therapy was made. First, the development of next-generation sequencing (NGS) technologies 
and large-scale projects such as The Cancer Genome Atlas (TCGA) resulted in a comprehensive 
characterization of the human cancer genomes. And second, novel drugs targeting immune 
checkpoint molecules have been approved in several malignancies and are showing remarkable 
clinical effects. These drugs augment T-cell activity by blocking cytotoxic T lymphocyte antigen-4 
(CTLA-4), programmed cell death protein 1 (PD-1), or PD-1 ligand. Long-term data of patients 
who received anti-CTLA-4 antibodies in unresectable or metastatic melanoma indicate curative 
potential in a fraction of patients (1). Moreover, efficacy of anti-PD-1 antibodies has been shown 
not only in melanoma, but in an increasing number of other cancers (2). Not surprisingly, there are 
now enormous efforts for the development of novel immunotherapeutic strategies with over 1,000 
clinical trials with monotherapies or combination therapies (3).
One specific advantage of cancer immunotherapy is the potential to adapt to the evolution of 
the tumor since specific T cells can develop which are targeting newly developed tumor clones. 
T cells recognize tumor-specific antigens bound to the major histocompatibility complex (MHC) 
molecules of tumor cells. Antigens with high tumoral specificity have the potential to elicit tumor-
specific immune responses and are, therefore, of great interest for cancer immunotherapeutic 
strategies, including therapeutic vaccines and engineered T cells. There are three classes of antigens 
with high tumoral specificity: (1) viral antigens that are derived from genes expressed in virus-
infected tumor cells; (2) cancer-germline antigens, also known as cancer-testis antigens. These 
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are proteins that are expressed only by germline cells and have 
aberrant expression in tumor cells; and (3) neoantigens, i.e., are 
peptides that are generated from somatic mutations. During 
tumor progression, mutations accumulating in the tumor 
genome can affect protein-coding genes and result in altered 
protein sequences. Mutated proteins are proteolytically cleaved 
into short peptides and presented on the tumor cell surface by 
the MHC—called human leukocyte antigen (HLA) in humans. 
These mutated neoantigens, which are present in the malignant 
cells but not in the normal cells can be recognized as foreign by 
tumor-infiltrating lymphocytes (TILs) and elicit potent tumor-
specific immune responses. Neoantigens released after tumor 
cell death initiate a number of processes that ultimately lead 
to T cells that recognize cancer cells through the interaction of 
distinct T-cell receptors (TCR) with specific neoantigen–MHC 
complexes.
The tumor–immune cell interaction can be conceptualized as 
a number of processes conceptualized as the cancer-immunity 
cycle (4). The first step in this cycle is the generation of neo-
antigens (neoepitopes) and, therefore, the identification and 
characterization of neoantigens is of utmost importance for 
deriving novel mechanistic insights on cancer immunity and 
developing efficient cancer immunotherapies. In this review, we 
give an overview of the current advances in the computational 
prediction of neoantigens and discuss the development of cancer 
immunotherapies targeting neoantigens, including vaccination, 
checkpoint therapy, and adoptive cell transfer.
QUANTiFYiNG NeOANTiGeNS USiNG 
NGS DATA
Neoantigens can be experimentally determined using proteomic 
analysis of MHC ligands by liquid chromatography and tandem 
mass spectrometry (5–7). However, this approach is labor 
intensive and requires large amount of material for the analysis, 
which is seldom available from human biopsies. Alternatively, 
when NGS data are available from matched tumor and normal 
samples, neoepitopes can be predicted by integrating four 
computational tasks: (i) prediction of somatic DNA mutations; 
(ii) identification of mutated proteins; (iii) in silico HLA typing; 
and (iv) selection of the mutated peptides with high binding 
affinity to the predicted MHC/HLA molecules and high expres-
sion of the mutation-encoding gene [see recent comprehensive 
review (8)]. Somatic DNA mutations are usually computed from 
whole-exome (WES) or whole-genome sequencing (WGS) data 
from matched tumor-normal samples using computational 
tools for variant detection, and can be further processed with 
software for variant annotation to predict the affected proteins 
(9). Patient-specific NGS data from WES, WGS, or RNA 
sequencing (RNA-seq) can be also used to predict HLA types 
with computational tools like Polysolver (10) and Optiptype 
(11), which are able to extract the reads covering the HLA 
locus and predict the major alleles at 4-digit resolution or more. 
Finally, machine learning algorithms such as NetMHCpan (12) 
trained on experimental data can be used to predict which short 
peptides spanning protein regions affected by mutations bind 
with high affinity to the predicted HLA types.
The single tools performing the three computational tasks 
described above require a number of intermediate steps for 
data preprocessing and formatting which is usually carried 
out in specialized bioinformatics labs. In order to broaden 
the utility of the computational genomics tools, a number of 
computational pipelines that integrate the individual steps 
were recently developed. Such pipelines for in silico prediction 
of personalized neoantigens from NGS data with different 
degrees of functionality include pVAC-seq (13), FRED 2 (14), 
INTEGRATE-neo (15), and MuPEXI (16). However, although 
an improvement to the use of individual steps, assembling 
analytical pipelines and executing workflows with a number 
of consecutive steps is laborious and depends on many param-
eter settings. The recently developed pipeline TIminer (17) 
integrates cutting-edge bioinformatics tools for the analysis 
of both, RNA-seq data and somatic DNA mutations in order 
to characterize the tumor–immune interface. This pipeline 
enables: (1) genotyping of HLAs using exome-sequencing 
or RNA-seq data, (2) prediction of tumor neoepitopes using 
specific HLA types and mutations, and (3) characterization of 
TILs from bulk RNA-seq data.
The available computational pipelines predict neoepitopes 
that bind to class-I MHC molecules. Peptides binding to class-I 
MHC molecules, which exist on almost all nucleated cells, are 
presented for recognition by cytotoxic CD8+ T  cells. Class-II 
MHC molecules are present only on professional antigen-
presenting cells, such as dendritic cells, macrophages, and 
B lymphocytes, and display antigens to CD4+ helper T  cells. 
Although coordinated CD4+ and CD8+ responses are required 
for tumor control and rejection, the suboptimal performance 
of the current algorithms for prediction of class-II neoantigens 
limits their translational potential for personalized cancer 
medicine. The need for better methods for prediction of class-II 
neoantigens has increased ever since studies showed that CD4+ 
T cells recognize a higher number of neoantigens than was pre-
viously known and can generate potent antitumor response (17). 
More recently, a proof-of-concept by Sahin et al. and Ott et al. 
using a combined strategy for class-I and class-II neoantigen 
prediction was presented (18, 19).
There are several challenges with MHC–peptide-binding 
prediction algorithms. First, experimental data from measure-
ments of the biochemical affinity of synthetic peptides, needed 
for the training of these algorithms, are limited for MHC class-II 
alleles. Therefore, while effective in predicting many epitopes, 
these approaches may nevertheless be limited in their accu-
racy due to the sparsity of both positive and negative training 
data sets and result in high false-positive rate. For example, in 
Robbins et  al., 229 tumor-specific neoepitopes were predicted 
across three melanoma patients, but only 11 of these neoepitopes 
elicited a T-cell response (20). In addition, these methods do not 
necessarily consider the endogenous processing and transport of 
peptides prior to HLA binding. In order to improve neoantigen 
predictions, Abelin et  al. developed a new biochemical and 
computational pipeline for LC–MS/MS analysis of endogenously 
processed HLA-associated peptides along with a predictor that 
outperformed current algorithms that are trained on peptide 
affinity data (21).
FiGURe 1 | Association between neoantigens and mutations from a 
pan-cancer analysis reported recently (25). The plot shows the results of the 
analysis of 6,726 patients from 19 solid cancers. The number of neoantigens 
per subject ranged from 1 to 15,035 and the number of mutations per MB 
per patients from 0.019 to 933.085.
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NeOANTiGeN LANDSCAPe iN SOLiD 
CANCeRS
Given the availability of NGS data from cancer samples from 
large-scale projects such as the TCGA, as well as the improved 
performance of the computational tools, a number of studies 
analyzed neoantigens and association with clinical parameters 
and molecular entities. A seminal work by Holt and colleagues 
showed an association between neoantigen load and survival (22). 
We recently generated high-resolution maps on neoantigens and 
the immunophenotypes in colorectal cancer (CRC) (23) using 
genomic data sets from the TCGA cohort (n =  598) (24). The 
neoepitopes were barely shared between patients: only 4% of the 
predicted neoepitopes were shared between 2 and more patients. 
The shared neoepitopes are identical peptides that originate from 
one or more genes. Importantly, we observed that the genetic 
basis of the tumors determines the tumor escape mechanisms. 
For example, hypermutated tumors had higher intratumor 
heterogeneity, indicating that the larger mutational load results 
not only in a larger neoantigen load but also in a more diverse 
neoepitope landscape, and therefore likely promotes T-cell acti-
vation and infiltration.
We then extended the analysis and characterized more than 
8,000 patients from the TCGA comprising 19 solid cancers (25) 
(results available at https://tcia.at). As expected, our pan-cancer 
analysis showed that the number of neoepitopes correlated 
with the mutational load. The results of this analysis are shown 
in Figure  1. Moreover, the number of neoepitopes correlated 
also with the infiltration of TILs. The fraction of neoepitopes 
generated from driver genes was 7.6%. Thus, the majority of 
neoepitopes had its origin in passenger genes. Similar to the 
CRC study, the results showed that the neoepitopes were seldom 
shared. From the total of 911,548 unique predicted neoepitopes, 
only 24 were common in more than 5% of patients. As expected, 
the most frequent predicted neoepitopes were induced by muta-
tions in driver genes, such as BRAF, RAS, and PIK3CA. Thus, the 
results show that the neoantigen landscape in solid cancers is not 
only highly diverse both, between and within cancers, but also 
extremely sparse. The sparsity of the neoantigen space clearly 
argues against vaccination strategy based on off-the-shelf vac-
cines. Rather, cancer vaccination strategies based on neoepitopes 
has to be personalized. This can be achieved by using whole-
exome NGS for the identification of somatic mutations and 
bioinformatic prediction of neoepitopes, followed by synthesis of 
peptide- or DNA/RNA-based vaccines. Proof of concept for this 
type of individualized cancer vaccination was recently shown in 
several clinical studies (18, 19, 26).
NeOANTiGeNS AND CANCeR 
iMMUNOTHeRAPY
Self-antigens that are aberrantly expressed in cancerous tissues 
can provoke an immune response and have been used in the 
past in clinical studies. However, expression of these antigens 
in normal tissues can initiate central and peripheral tolerance 
mechanisms. Lately, more efforts have been focused on anti-
gens derived from mutated proteins. Since T cells recognizing 
neoantigens are not influenced by central immune tolerance 
because of the lack of expression in healthy tissues, targeting 
of tumor neoantigens may be more specific and less toxic than 
other approaches, making neoantigens attractive targets for 
immunotherapy, including therapy with antibodies directed 
against immune checkpoint blockers, therapeutic vaccination, 
or adoptive T-cell transfer with TCR-engineered neoantigen-
specific T cells.
Neoantigens and Response to Therapy 
with Checkpoint Blockers
An increasing number of studies have shown a strong association 
of the mutation/neoantigen burden with TIL infiltration and 
activity, as well as better response to therapy and overall survival 
in non-small cell lung cancer (NSCLC) and melanoma patients 
(27–29). Both types of cancers accumulate high number of 
mutations as a result of exposure to mutagens, such as tobacco 
smoke and ultraviolet light. Tumors with microsatellite instabil-
ity due to deficiency in the mismatch repair system show high 
mutational burden, T-cell infiltration, improved survival, and 
durable clinical benefit when treated with checkpoint blockers. 
Similarly, tumors with mutations in other DNA repair pathways 
(30–32) showed an enhanced T-cell response and better response 
to checkpoint blockers. A recent study by Le and colleagues 
provided further evidence of the sensitivity of mismatch-repair-
deficient cancers to checkpoint blockade, irrespectively of the 
tissue of origin (33). The authors evaluated the efficacy of anti-
PD-1 treatment in patients with mismatch repair deficiency from 
12 different cancer entities and reported objective responses in 
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53% and complete responses in 21% of these patients. Moreover, 
they demonstrated through functional analysis in a responding 
patient that tumor-reactive lymphocytes were directed against 
mutated neoantigens. As a comparison, MSS CRC and cancers 
with low mutational load such as prostate cancer have shown 
little or no benefit from immunotherapies, providing additional 
evidence for the importance of neoantigens in the antitumor 
immune response. However, there are also cases of cancers 
with high neoantigen burden showing no response to immune 
checkpoint therapies [e.g., 50% of the microsatellite instable 
(MSI) cancers], as well as cancers characterized by low neoan-
tigen load that are susceptible to immunotherapy (34). Thus, it 
can be argued that the high neoantigen load represents merely 
a higher likelihood of the presence of immunogenic neoantigen 
suggesting that neoantigen landscape alone is not sufficient in 
predicting immunotherapy responses.
Cancer vaccination
Individualized vaccines, designed to present neoantigens to 
prime and activate dendritic cells have also been used to selec-
tively target neoantigens. Vaccines have been shown to both 
expand pre-existing neoantigen-specific T-cell populations as 
well as broaden the TCR repertoire. In addition to enhancing 
the strength and persistence of T  cells, vaccines can elicit an 
immune response for neoantigens that were undetectable 
prior to vaccination (26). Therefore, even if the neoantigens 
that spontaneously induce T-cell responses are lost due to 
immunoediting, the neoantigens that do not naturally elicit 
a response can serve as targets for vaccines (35). Two recent 
studies (18, 19), used vaccines based on neoantigens recognized 
by CD4+ and/or CD8+ T  cells to demonstrate that personal 
neoantigen vaccines, alone or in combination with checkpoint 
blockade, can induce both effective and safe immune response. 
The authors reported T-cell infiltration induced by vaccination 
and specific killing of tumor cells expressing neoantigens. Ott 
et al. used synthetic long 15–30-mers peptides and immunized 
six melanoma patients, two of which had lung metastases (35). 
Four out of six patients had no disease recurrence, whereas 
metastatic patients were further treated with anti-PD-1 therapy 
and showed complete tumor regression. Sahin et  al. used an 
RNA-based approach using predicted neoantigens recognized 
by CD4+ and CD8+ T  cells in 13 melanoma patients (18). 
Neoantigen-based vaccination reduced metastatic events and 
caused objective response in two over five metastatic patients 
and, even more strikingly, a complete response in a third 
patient treated with the vaccine in combination with anti-PD-1 
immunotherapy. Both reports further indicate that neoantigens 
are important targets for mediating response to checkpoint 
therapies and, additionally, that the tumor-reactive T cells tar-
get diverse tumor clones, thereby dealing with extensive tumor 
heterogeneity.
Adoptive T Cell Transfer
Neoantigens can be used to expand neoantigen-specific T cells 
in  vitro for use in adoptive T-cell transfer. Several studies 
reported tumor regression achieved by transfer of autologous TILs 
resected from patients with metastatic melanoma (20, 36). The 
Rosenberg group demonstrated dramatic tumor regression in 
a metastatic cholangiocarcinoma patient treated with a per-
sonalized adoptive cell transfer, where over 95% of autologous 
T cells consisted of CD4+ T cells that recognized a single HLA 
class-II-restricted neoantigen (37). They also demonstrated the 
therapeutic efficacy of neoantigen-specific CD4+ T  cells. In a 
study by van Rooij et al., in which exome sequencing and MHC 
tetramer screening was used, compelling evidence was provided 
that immunotherapy with checkpoint blockers in a melanoma 
patient induces expansion of already existing T cells which are 
targeting neoantigens (38).
Despite the success of immunotherapies targeting neoan-
tigens, many questions remain unanswered. To begin with, 
only few of the predicted neoantigens elicit potent immune 
responses. Even though only a small percentage of the in silico 
predicted neoantigens are actually immunologically recognized, 
Strønen et al. provided evidence of the existence of a neglected 
neoantigen repertoire that induces T-cell reactivity and may 
broaden neoantigen-specific T-cell reactivity and enable the 
targeting of neoantigens that have not been recognized by the 
patient’s own immune system (39). This is further supported by 
two other studies (18, 35) that showed that responses against 
neoantigens can be induced de novo. One possible explanation 
for the hidden neoantigen repertoire is the immunodominance 
of tumor antigens: the immune system targets particular tumor 
antigens but ignores others (40), a phenomenon that often 
occurs with viral antigens. In addition, lack of T-cell priming 
against tumor-associated antigens can result in the exclusion 
of T  cells from the tumor microenvironment. For example, 
Spranger et  al. (39) reported that oncogenic WNT/β-catenin 
signaling pathway prevents T-cell and CD103+ DC infiltration 
in melanoma and generates resistance to checkpoint blockade 
therapy.
In conclusion, genomic approaches can facilitate the develop-
ment of personalized immunotherapies directed at neoantigens. 
Therapeutic stimulation of broad neoantigen-specific T-cell 
responses through vaccines targeting multiple antigens could 
help overcome the effects of tumor heterogeneity as well as avoid 
resistance, by providing broader coverage of the whole tumor 
cell population. As highly homogeneous tumors have been 
shown to be more immunogenic and since clonal neoantigens 
seem to drive antitumor responses following therapy with 
antibodies against immune checkpoints, a potential approach is 
to target clonal neoantigens, i.e., those that are expressed in all 
tumor cells within a patient, in order to overcome the significant 
challenge posed by intratumor heterogeneity. However, different 
cancers undergo different evolutionary trajectories: some are 
dominated by Darwinian selection pressures that shape their 
clonal composition, whereas others follow neutral evolution. 
In order to successfully target the whole tumor population and 
prevent escape of resistant clones, comprehensive genomic and 
immunogenomic analyses of pre- and post-treatment samples 
are needed for longitudinally evaluating changes in the tumor. 
Ultimately, a deeper understanding of the evolutionary and 
immune-related forces that shape the tumor progression will 
be fundamental to improve the efficacy of immunotherapy and 
minimize resistance.
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TUMOR HeTeROGeNeiTY, 
iMMUNOeDiTiNG, AND ACQUiReD 
ReSiSTANCe TO CANCeR 
iMMUNOTHeRAPY
Tumor Heterogeneity
Mutational processes and genomic instability can result in 
extensive tumor heterogeneity, which has important clinical 
and immunological implications. While it is well established 
that intratumoral heterogeneity has an impact on the response 
of cancer patients to treatments with targeted therapies (41–43), 
the role of the immune surveillance and sensitivity of the 
tumors to therapy with checkpoint blockers are only beginning 
to emerge. Recent studies provided insights into the effect on 
intratumoral heterogeneity on the immune response and showed 
that the mutational load in combination with the intratumoral 
heterogeneity is a better predictor of response to checkpoint 
blockers than the neoantigen burden alone. More homogeneous 
tumors and tumors with high clonal neoantigen burden have 
been associated with higher T-cell infiltration, better prognosis, 
and better sensitivity to immunotherapeutic approaches (44–46). 
McGranahan et  al. demonstrated that tumors from melanoma 
and NSCLC patients enriched with clonal neoantigens displayed 
an inflamed phenotype and were more sensitive to checkpoint 
blockade therapy (44). These findings raise the question whether 
immunotherapy will be also effective in heterogeneous tumors as 
the targeting of subclonal neoantigens by cytotoxic T cells is not 
sufficient to eradicate the whole tumor.
Although intratumoral heterogeneity presents a challenge 
for conventional and targeted therapies, increased mutational 
diversity may provide a beneficial opportunity for immuno-
therapies by generating potential neoantigens that can be recog-
nized by T cells (47). Very high intratumoral heterogeneity has 
also been correlated with better prognosis, implying a possible 
trade-off between acquiring an immunogenic mutation that can 
elicit an immune response or a driver mutation that can confer a 
fitness advantage to the tumor cells (45). Highly heterogeneous 
tumors are possibly driven by neutral evolution, resulting into 
many subclonal mutations with little or no impact on cancer 
progression, but potentially generate neoantigens able to elicit 
an immune response (48).
Cancer immunoediting and Acquired 
Resistance to immunotherapy
The cancer immunoediting hypothesis postulates a dual role of 
immunity in the complex interaction between the tumor and 
the host: the immune system, by recognizing tumor-specific 
antigens, not only can protect the host by eliminating tumor cells 
but can also sculpt the developing tumor by editing the cancer 
genome, and thereby modifying the heterogeneity of the tumor. 
Strong immunoediting would render tumors more homogene-
ous by eradicating immunogenic clones (49). Elimination 
of neoantigens by a T  cell-dependent selection process has 
been suggested as a mechanism of cancer immunoediting in 
mouse models and human studies (50). Experimental evidence 
from mouse models and human studies now provides strong 
support for the existence of cancer immunoediting in many 
cancers.
The definitive work supporting the existence of cancer 
immu noediting was published in 2001 by the Schreiber lab and 
showed that immunodeficient Rag2−/− mice develop spontane-
ous and carcinogen-induced tumors more rapidly and more 
frequently than genetically matched wild-type controls (51). 
Moreover, the tumors arising in immunodeficient animals were 
frequently rejected following transplantation into immuno-
competent recipients, however, when implanted into secondary 
immunodeficient hosts the effects were not observable. Hence, 
it seems that tumors from those mice were more immunogenic 
compared to the tumors from wild-type mice. In a more recent 
study, cancer immunoediting was investigated in the same 
mouse model of sarcoma using NGS of the tumor exome and 
algorithms for predicting neoantigens (52). Their results dem-
onstrated that MCA tumors with a mutant form of spectrin β2 
(also known as SPTBN1) were rejected, whereas other tumors 
developed because of a T-cell-dependent selection of tumor 
cells that lacked expression of the spectrin β2 antigen. Similar 
observations were obtained using an oncogene-driven model of 
cancer in genetically engineered, immunodeficient mice (53) in 
which primary sarcomas were edited through selection of cells 
that either did not express antigens or were unable to present 
antigens to T  cells. These studies demonstrated that dynamic 
interactions between tumors cells and T  cells lead to immu-
noediting. In contrast to carcinogen-induced highly mutated 
tumors, non-immunogenic tumors with low neoantigen burden 
do not undergo spontaneous immunoediting (54). In addition, 
longitudinal samples of pre- and post-treatment samples have 
shown that different therapies also impose strong selective pres-
sure that can affect the tumor clonal architecture and change the 
evolutionary path of tumor progression. For instance, patients 
with a high number of subclonal mutations due to treatment 
with an alkylating agent were reported to have a poor response 
to anti-CTLA-4 therapy (44).
Even though immunoediting is more difficult to study in 
humans, there have been several studies exploring the neoanti-
gen dynamics over time and before and after therapy in patients. 
A pan-cancer study of TCGA patients in which observed and 
expected numbers of neoepitopes were analyzed provided 
the first evidence of immunoediting in human cancers (28). 
The authors showed that neoantigens are depleted in some 
cancer types relative to their expected numbers, indicating 
immune-mediated elimination of tumor subclones that contain 
neoantigens. Using a similar approach, we recently provided 
additional data that support the existence of immunoediting 
in MSI CRC (55).
More recent studies explored the evolution of the neoantigen 
landscape over time and in response to therapy-induced immune 
editing. Verdegaal et al., using longitudinal samples from two 
melanoma patients treated by adoptive T-cell transfer, observed 
loss of the mutant allele in two cases and reduced expression 
of T-cell-recognized neoantigens in another one, suggest-
ing potential T-cell dependent selection of antigen-negative 
variants (56) However, they additionally reported an increased 
expression of one mutated gene over time. Anagnostou et al. 
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analyzed matched pretreatment and resistant tumors in patients 
with NSCLC that acquired resistance following a response to 
therapy targeting PD-1 and/or CTLA-4 (57). The authors iden-
tified immunogenic neoepitopes that were not detectable in the 
resistant tumors due to an elimination of tumor subclones or 
chromosomal deletions, and proposed therapy-induced immu-
noediting of neoantigens as a mechanism of acquired resistance 
to checkpoint blockade therapy.
Apart from antigen loss, other immunoediting mechanisms 
such as defects in antigen processing and presentation (58) or 
in pathways involved in interferon receptor signaling (59) may 
give rise to acquired resistance to therapy. Gao et al. reported that 
melanoma patients failed to respond to anti-CTLA-4 therapy due 
to the loss of IFN-γ signaling caused by genomic defects, such 
as loss-of-function mutations in JAK1/JAK2 or copy-number 
alterations in IFN-γ pathway genes (60). In another recent study, 
pre-treatment and relapse samples from melanoma patients 
subjected to anti-PD-1 blockade therapy were analyzed to iden-
tify resistance-associated mutations. The results showed clonal 
selection of loss-of-function mutations in JAK1 and JAK2 in two 
patients, which led to lack of response to interferon gamma, and 
a truncating mutation in the antigen-presenting protein B2M 
in another case, resulting in decreased immune cell recognition 
of tumor cells (61). Moreover, vaccines can increase tumor- 
infiltrating CD8+ T cells that secrete IFNγ, leading to upregula-
tion of the PD1–PDL1 pathway and other inhibitory pathways 
(62) and creating a negative feedback loop that can suppress 
tumor immunity.
OUTLOOK
In the past few years, driven by novel mechanistic insights into 
cancer immunology and data from clinical trials with check-
point blockers, tumor neoantigens came into focus in cancer 
immunology. It became obvious that targeting neoantigens can 
improve antitumor immunity and minimize off-target toxici-
ties. However, several issues need to be addressed in order to 
fully harness the power of cancer immunotherapy by targeting 
neoantigens. First, and most important, considerable research 
efforts are required to identify the rules that govern the immu-
nogenicity of neoantigens. The majority of the experimentally 
verified neoantigens that induce antitumor responses are from 
passenger genes, likely due to the large fraction of passenger 
mutations (roughly about 90%) compared to driver muta-
tions. Major drawback for developing computational tools 
for predicting immunogenicity of neoantigens is the dearth 
of available data. As of today, there are probably few hundred 
doublets (HLA-neoantigens) and about a dozen triplets (HLA-
neoantigens-αβTCR sequences) available for training. Thus, 
novel medium-to-high-throughput methods are required 
to generate large enough datasets for data-driven modeling. 
Second, improved computational methods need to be developed 
to accurately predict class-II MHC binding neoantigens. Again, 
major limitation is the limited availability of both positive and 
negative training data sets. And third, one almost completely 
unexplored area are neoantigens that are post-translationally 
modified and the impact of these epitopes on the antitumor 
immunity. Efforts are underway to tackle these challenges and 
we will very likely witness in near future exciting developments 
and discoveries, which will ultimately result in benefit for an 
individual patient.
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